Cangrelor for emergent carotid stenting during stroke thrombectomy: a comparative analysis versus glycoprotein IIb/IIIa inhibitors or aspirin monotherapy.
[en] [en] BACKGROUND: Periprocedural antiplatelet treatment is a key determinant for the risk-benefit balance of emergent carotid artery stenting (eCAS) during stroke endovascular treatment (EVT). We aimed to assess the safety and efficacy profile of cangrelor compared with glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors or aspirin monotherapy.
METHODS: Data were extracted from the Endovascular Treatment in Ischemic Stroke (ETIS) registry, a prospective nationwide observational registry of stroke EVT in France. Included patients were treated with eCAS for anterior circulation tandem lesions between January 2015 and June 2023 and received periprocedural treatment with cangrelor, GPIIb/IIIa inhibitors or aspirin monotherapy. The primary outcome was functional outcome at 90 days, assessed by the modified Rankin Scale (mRS). Secondary outcomes included intracranial recanalization, hemorrhagic transformation and carotid stent patency at day 1.
RESULTS: Of the 1687 patients treated, 384 met the inclusion criteria: 91 received cangrelor, 77 received GPIIb/IIIa inhibitors and 216 aspirin monotherapy. Cangrelor was associated with a negative shift in the distribution of mRS scores compared with GPIIb/IIIa inhibitors (aOR 0.48, 95% CI 0.25 to 0.94, P=0.033). Compared with aspirin, cangrelor improved carotid stent patency at day 1 (aOR 4.00, 95% CI 1.19 to 14.29, P=0.025) but showed no significant differences in clinical outcomes. There were no differences in outcomes between full dose and low dose cangrelor. GPIIb/IIIa inhibitors demonstrated higher odds of functional independence (aOR 2.56, 95% CI 1.08 to 6.25, P=0.033) compared with aspirin.
CONCLUSIONS: This registry-based study indicates a potential trend towards lower odds of favorable clinical outcomes with cangrelor treatment compared with GPIIb/IIIa inhibitors. However, these findings should be interpreted with caution due to potential selection bias and warrant further research for validation.
Disciplines :
Neurology
Author, co-author :
Pop, Raoul ; Department of Interventional Neuroradiology, Strasbourg University Hospitals, Strasbourg, France pop.raoul@gmail.com ; Interventional Radiology, IHU Strasbourg, Strasbourg, France ; INSERM UMR_S1255, Etablissement Français du Sang, Strasbourg, France
Finitsis, Stephanos Nikolaos ; Department of Neuroradiology, Aristotle University of Thessaloniki, Thessalonike, Greece
Marnat, Gaultier ; Interventional and Diagnostic Neuroradiology, CHU Bordeaux GH Pellegrin, Bordeaux, France
Derraz, Imad ; Neuroradiology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
Cognard, Christophe ; Diagnostic and Therapeutic Neuroradiology, CHU Toulouse, Toulouse, France
Calviere, Lionel; Stroke Unit, CHU Toulouse, Toulouse, France
Caroff, Jildaz ; Department of Interventional Neuroradiology - NEURI Brain Vascular Center, Bicêtre Hospital, APHP, Le Kremlin Bicêtre, France
Clarençon, Frédéric; Radiology, Sorbonne Universite, Paris, France ; Neuroradiology, Hopital Universitaire Pitie-Salpetriere, Paris, France
Delvoye, François ; Université de Liège - ULiège > Département des sciences cliniques ; Neurointerventional Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
Consoli, Arturo ; Diagnostic and Interventional Neuroradiology, Hospital Foch, Suresnes, France
Lapergue, Bertrand; Neurology, Hospital Foch, Suresnes, France
Gory, Benjamin; Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nancy, Nancy, France ; Radiology, Université de Lorraine, Nancy, France ; IADI, INSERM U1254, Nancy, France
Cangrelor for emergent carotid stenting during stroke thrombectomy: a comparative analysis versus glycoprotein IIb/IIIa inhibitors or aspirin monotherapy.
Gory B, Haussen DC, Piotin M, et al. Impact of intravenous thrombolysis and emergent carotid stenting on reperfusion and clinical outcomes in patients with acute stroke with tandem lesion treated with thrombectomy: a collaborative pooled analysis. Eur J Neurol 2018;25:1115–20.
Papanagiotou P, Haussen DC, Turjman F, et al. Carotid stenting with antithrombotic agents and intracranial thrombectomy leads to the highest recanalization rate in patients with acute stroke with tandem lesions. JACC Cardiovasc Interv 2018;11:1290–9.
Wilson MP, Murad MH, Krings T, et al. Management of tandem occlusions in acute ischemic stroke - intracranial versus extracranial first and extracranial stenting versus angioplasty alone: a systematic review and meta-analysis. J Neurointerv Surg 2018;10:721–8.
Farooqui M, Zaidat OO, Hassan AE, et al. Functional and Safety Outcomes of Carotid Artery Stenting and Mechanical Thrombectomy for Large Vessel Occlusion Ischemic Stroke With Tandem Lesions. JAMA Netw Open 2023;6:e230736.
Zhu F, Hossu G, Soudant M, et al. Effect of emergent carotid stenting during endovascular therapy for acute anterior circulation stroke patients with tandem occlusion: A multicenter, randomized, clinical trial (TITAN) protocol. Int J Stroke 2021;16:342–8.
Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J 2019;4:6–12.
Pop R, Burel J, Finitsis SN, et al. Comparison of three antithrombotic strategies for emergent carotid stenting during stroke thrombectomy: a multicenter study. J Neurointerv Surg 2023;15:e388–95.
Marnat G, Finistis S, Moreno R, et al. Aspirin versus aggressive antiplatelet therapy for acute carotid stenting plus thrombectomy in tandem occlusions: ETIS Registry results. J NeuroIntervent Surg 2023;15:e248–54.
Schirmer CM, Bulsara KR, Al-Mufti F, et al. Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update. J Neurointerv Surg 2023;15:1155–62.
Caroff J, Aubert L, Lavenu-Bombled C, et al. Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey. J Neurointerv Surg 2023;15:402–7.
Pop R, Severac F, Hasiu A, et al. Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy. Interv Neuroradiol 2023;29:268–76.
De Luca L, Steg PG, Bhatt DL, et al. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. JAHA 2021;10.
Cagnazzo F, Radu RA, Derraz I, et al. Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures. J NeuroIntervent Surg 2024;16:88–93.
Marnat G, Finistis S, Delvoye F, et al. Safety and Efficacy of Cangrelor in Acute Stroke Treated with Mechanical Thrombectomy: Endovascular Treatment of Ischemic Stroke Registry and Meta-analysis. AJNR Am J Neuroradiol 2022;43:410–5.
Marnat G, Delvoye F, Finitsis S, et al. A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions. AJNR Am J Neuroradiol 2021;42:1452–7.
Cervo A, Ferrari F, Barchetti G, et al. Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A “Real Life” Single-Center Experience. AJNR Am J Neuroradiol 2020;41:2094–9.
Jumaa MA, Rodriguez-Calienes A, Dawod G, et al. Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions. J Stroke Cerebrovasc Dis 2023;32:107438.
van Dellen D, Tiivas CAS, Jarvi K, et al. Transcranial Doppler ultrasonographydirected intravenous glycoprotein IIb/IIIa receptor antagonist therapy to control transient cerebral microemboli before and after carotid endarterectomy. Br J Surg 2008;95:709–13.
Junghans U, Siebler M. Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Circulation 2003;107:2717–21.
Desilles J-P, Syvannarath V, Di Meglio L, et al. Downstream Microvascular Thrombosis in Cortical Venules Is an Early Response to Proximal Cerebral Arterial Occlusion. J Am Heart Assoc 2018;7:e007804.
Wu C, Sun C, Wang L, et al. Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis. Stroke 2019;50:3481–7.
Zhao W, Che R, Shang S, et al. Low-Dose Tirofiban Improves Functional Outcome in Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy. Stroke 2017;48:3289–94.
Sang H, Cao Z, Du J, et al. Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials. Stroke 2024;55:856–65.
Zi W, Song J, Kong W, et al. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med 2023;388:2025–36.
Zhao W, Li S, Li C, et al. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol 2024;81:594–602.
Medina-Rodríguez M, Moniche F, de Albóniga-Chindurza A, et al. Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. Eur Stroke J 2023;8:380–6.
Allard J, Delvoye F, Pop R, et al. 24-Hour Carotid Stent Patency and Outcomes After Endovascular Therapy: A Multicenter Study. Stroke 2023;54:124–31.
Diana F, Abdalkader M, Behme D, et al. Antithrombotic regimen in emergent carotid stenting for acute ischemic stroke due to tandem occlusion: a meta-analysis of aggregate data. J Neurointerv Surg 2024;16:243–7.
Farooqui M, Divani AA, Galecio-Castillo M, et al. Safety Outcomes of Antiplatelet Therapy During Endovascular Treatment of Tandem Lesions in Acute Ischemic Stroke Patients. Transl Stroke Res 2023.:10.1007/s12975-023-01214-9.
Wallocha M, Chapot R, Nordmeyer H, et al. Treatment Methods and Early Neurologic Improvement After Endovascular Treatment of Tandem Occlusions in Acute Ischemic Stroke. Front Neurol 2019;10:127.
Fahed R, Redjem H, Blanc R, et al. Endovascular Management of Acute Ischemic Strokes with Tandem Occlusions. Cerebrovasc Dis 2016;41:298–305.
